Some research studies should be criminal. A good case in point is this study in an article found in Phys.Org, UC San Diego to study accelerated aging in schizophrenia.
Researchers at the Stein Institute for Research on Aging at the University of California, San Diego have received a $4 million grant from the National Institute of Mental Health (NIMH), part of the National Institutes of Health, to study accelerated biological aging in schizophrenia.
Accelerated biological aging? They’re not really studying accelerated aging, are they? The short answer to this question is no. Poor health is often attributed to the psychiatric label that is actually the result, as is the case here, of the drugs given to treat the label. The researchers attribute this poor health falsely to the label as a method of getting more funding and of better deceiving the general public.
Scientists have long observed that schizophrenia is more than a brain disease, as it also affects a wide range of physical functions and entails more rapid biological aging. A number of studies have suggested that physiological changes seen throughout the body occur at an earlier age in people with schizophrenia. For example, young adults suffering from this mental condition are prone to diseases associated with growing older, such as diabetes and cardiovascular problems.
Suddenly we’re expected to digest the oxymoronic suggestion that there are old young people running around in the mental health system. Actually it is a well known fact that a metabolic condition associated with the use of the atypical neuroleptic drugs developed in the 1990s is the culprit. These drugs have a tendency to cause an excessive weight gain which accompanies the diseases mentioned in the article and results in early mortality. What these researchers will actually be studying is the iatrogenic ill health that doctors are directly responsible for causing. This is the research equivalent of poisoning somebody so that you can observe him or her in the process of dying.
To unravel biological mechanisms underlying faster aging, [principal investigator Dilip V.] Jeste and colleagues will measure and analyze a panel of biomarkers associated with insulin dysregulation, inflammation, oxidative stress, and cell aging. The last study involves measuring the length of telomeres – regions of DNA that protect the ends of chromosomes from deterioration and have been linked to longevity. In addition, researchers will investigate the effects of factors related to chronicity of schizophrenia, such as cumulative effects of medication.
There is an easy way to de-accelerate what these researchers are calling an aging process, and that is simply by reducing the dosage of neuroleptic drug that the research subjects are being given. The “cumulative effects of medication” are where the effects of the drugs have to be accumulated over the long-term in a subject. You could do the same thing with persistent low doses of potassium cyanine. “Chronicity” itself is related to the use of these drugs for what is termed “symptom management”. This “symptom management” takes place basically because the condition is thought to so severe in an individual as to place him or her beyond recovery.
The NIMH should have better places to put its money than into studies that damage people just so that damage can be studied. I can’t begin to express how unethical this sort of practice is. I would imagine that the impetus behind this research might be the development of a drug to de-accelerate the ill health that is brought on by psychiatric treatment that could be added to any drug cocktail a mental health consumer might be put on. This additional drug is proposed in order to rake in kickbacks from the drug industry that would not be there if the patient were detoxified. Detoxification, of course, comes with a reduction of drugs.
Filed under: Mental Health Care, Psychiatric Drugs, Research, Biological Psychiatry, Children and Adolescents, Recovery, Health Care, College and University, Violence, Disinformation, Pharmaceutical Company, Polypharmacy, Conflict of Interest, Brain Damage | 9 Comments »